Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats.
about
Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the LiteraturePhysiologically based pharmacokinetic modeling of dibromoacetic acid in F344 rats.The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?Toxicity and carcinogenicity of the water disinfection byproduct, dibromoacetic acid, in rats and miceTrichloroethylene risk assessment: a review and commentary.Multiple peaking phenomena in pharmacokinetic disposition.A Mechanism-Based Pharmacokinetic Enzyme Turnover Model for Dichloroacetic Acid Autoinhibition in Rats.Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo.Functional classification and biochemical characterization of a novel rho class glutathione S-transferase in Synechocystis PCC 6803Kinetics of trihalogenated acetic acid metabolism and isoform specificity in liver microsomes.Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes.Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study.
P2860
Q33436238-ADEF01E3-D076-4F1A-BB54-C30BA12392E0Q33759163-151EA91D-37A5-4FAE-9CE1-B7E284975458Q34580854-34E6262F-E234-4528-B190-C97CFE97F743Q35866956-FF7A43C3-C900-43F7-9319-AF57289EA2D3Q37620349-AD2FE052-2013-492E-9B7E-6515F19CE8A5Q37756115-A1769249-39E7-492D-BD67-8E7C7D110416Q38978157-1E9D5A86-154F-4BAA-8469-7476E864BDE4Q38988403-D15DCD6C-A779-47B9-9193-DDAA094678E4Q39835139-54C86A09-8EED-415F-B33B-55AAF383A5DAQ41429685-305018F3-BE21-49AC-AD05-4A8E3BAD2898Q42726702-B8A8C85A-768F-4FF4-BD08-45CCA42F1EBFQ44692833-BC2823F8-72D5-4CE0-A61E-E40D4133F111Q51227133-A50225E8-A1B7-4D5B-899E-45C47510B939
P2860
Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Low-dose pharmacokinetics and ...... ive and GST-zeta-depleted rats
@nl
Low-dose pharmacokinetics and ...... ve and GST-zeta-depleted rats.
@ast
Low-dose pharmacokinetics and ...... ve and GST-zeta-depleted rats.
@en
type
label
Low-dose pharmacokinetics and ...... ive and GST-zeta-depleted rats
@nl
Low-dose pharmacokinetics and ...... ve and GST-zeta-depleted rats.
@ast
Low-dose pharmacokinetics and ...... ve and GST-zeta-depleted rats.
@en
prefLabel
Low-dose pharmacokinetics and ...... ive and GST-zeta-depleted rats
@nl
Low-dose pharmacokinetics and ...... ve and GST-zeta-depleted rats.
@ast
Low-dose pharmacokinetics and ...... ve and GST-zeta-depleted rats.
@en
P2860
P3181
P356
P1476
Low-dose pharmacokinetics and ...... ve and GST-zeta-depleted rats.
@en
P2093
Irvin R Schultz
Shakil A Saghir
P2860
P304
P3181
P356
10.1289/EHP.02110757
P407
P577
2002-08-01T00:00:00Z